CU22921A1 - Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales - Google Patents
Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectalesInfo
- Publication number
- CU22921A1 CU22921A1 CU1999196A CU1999196A CU22921A1 CU 22921 A1 CU22921 A1 CU 22921A1 CU 1999196 A CU1999196 A CU 1999196A CU 1999196 A CU1999196 A CU 1999196A CU 22921 A1 CU22921 A1 CU 22921A1
- Authority
- CU
- Cuba
- Prior art keywords
- murine
- antibody
- ior
- diagnosis
- recombinant antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G01N33/5753—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado, contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico para las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas. Para ello la presente invención proporciona una composición que contiene anticuerpos monoclonales reducidos que reconocen el antígeno ior C2 y un ligando débil, el MDP con el agente reductor Sn2+ para realizar el radiomarcaje del anticuerpo con Tc-99m, Re-186, R-188 y sus similares, útil para el diagnóstico por inmunogammagrafía y radioinmunoterapia de tumores colorrectales, metástasis y recidivas.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
| ARP000105994A AR026463A1 (es) | 1999-11-16 | 2000-11-14 | ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2 |
| PCT/CU2000/000004 WO2001036485A2 (es) | 1999-11-16 | 2000-11-16 | Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales |
| BR0007827-1A BR0007827A (pt) | 1999-11-16 | 2000-11-16 | Anticorpos e fragmento fv que reconhecemantìgeno ior c2 |
| EA200100782A EA005169B1 (ru) | 1999-11-16 | 2000-11-16 | РЕКОМБИНАНТНОЕ АНТИТЕЛО, ВЗАИМОДЕЙСТВУЮЩЕЕ С АНТИГЕННЫМ КОМПЛЕКСОМ IOR C2, Fv- ФРАГМЕНТ УКАЗАННОГО АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP00977398A EP1174441A2 (en) | 1999-11-16 | 2000-11-16 | Antibodies and fv fragment recognizing antigen ior c2 |
| KR1020017008965A KR100827627B1 (ko) | 1999-11-16 | 2000-11-16 | 항원 아이오알 시2를 인식하는 항체 및 에프브이 단편 |
| MXPA01007261A MXPA01007261A (es) | 1999-11-16 | 2000-11-16 | Anticuerpos y fragmentos fv que reconocen el antigeno ior c2. |
| CNB008039542A CN1230446C (zh) | 1999-11-16 | 2000-11-16 | 识别抗原ior c2的抗体和fv片段 |
| CO00087150A CO5280154A1 (es) | 1999-11-16 | 2000-11-16 | Anticuerpos y fragmento fv que reconocen el antigeno ior c2 |
| CA002359577A CA2359577A1 (en) | 1999-11-16 | 2000-11-16 | Antibodies and fv fragment recognizing antigen ior c2 |
| JP2001538974A JP2003514831A (ja) | 1999-11-16 | 2000-11-16 | 抗原ＩＯＲＣ２を認識する抗体およびＦｖフラグメント |
| US09/889,480 US6891023B1 (en) | 1999-11-16 | 2000-11-16 | Antibodies and Fv fragment recognizing antigen IOR C2 |
| AU15130/01A AU783622B2 (en) | 1999-11-16 | 2000-11-16 | Antibodies and FV fragment recognizing antigen IOR C2 |
| TW089126622A TWI233440B (en) | 1999-11-16 | 2001-01-30 | Antibodies and FV fragment that recognise IOR C2 antigen |
| ZA200105803A ZA200105803B (en) | 1999-11-16 | 2001-07-13 | Antibodies and FV fragment recognizing antigen IOR C2. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU22921A1 true CU22921A1 (es) | 2004-02-20 |
Family
ID=5459527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6891023B1 (es) |
| EP (1) | EP1174441A2 (es) |
| JP (1) | JP2003514831A (es) |
| KR (1) | KR100827627B1 (es) |
| CN (1) | CN1230446C (es) |
| AR (1) | AR026463A1 (es) |
| AU (1) | AU783622B2 (es) |
| BR (1) | BR0007827A (es) |
| CA (1) | CA2359577A1 (es) |
| CO (1) | CO5280154A1 (es) |
| CU (1) | CU22921A1 (es) |
| EA (1) | EA005169B1 (es) |
| MX (1) | MXPA01007261A (es) |
| TW (1) | TWI233440B (es) |
| WO (1) | WO2001036485A2 (es) |
| ZA (1) | ZA200105803B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| MX2008010942A (es) * | 2006-02-28 | 2008-09-03 | Nymox Corp | Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas. |
| WO2012147965A1 (ja) * | 2011-04-28 | 2012-11-01 | 独立行政法人理化学研究所 | 生物材料を透明化する方法、及びその利用 |
| WO2012161143A1 (ja) | 2011-05-20 | 2012-11-29 | 独立行政法人理化学研究所 | 生物材料用透明化試薬、及びその利用 |
| US10267714B2 (en) | 2013-08-14 | 2019-04-23 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US6071020A (en) | 1996-03-07 | 2000-06-06 | Agfa-Gevaert | Apparatus for the processing of photographic sheet material |
| CU22640A1 (es) * | 1996-03-12 | 2000-12-22 | Centro Inmunologia Molecular | Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas |
-
1999
- 1999-11-16 CU CU1999196A patent/CU22921A1/es unknown
-
2000
- 2000-11-14 AR ARP000105994A patent/AR026463A1/es active IP Right Grant
- 2000-11-16 WO PCT/CU2000/000004 patent/WO2001036485A2/es not_active Ceased
- 2000-11-16 JP JP2001538974A patent/JP2003514831A/ja active Pending
- 2000-11-16 CO CO00087150A patent/CO5280154A1/es active IP Right Grant
- 2000-11-16 BR BR0007827-1A patent/BR0007827A/pt not_active Application Discontinuation
- 2000-11-16 KR KR1020017008965A patent/KR100827627B1/ko not_active Expired - Fee Related
- 2000-11-16 CA CA002359577A patent/CA2359577A1/en not_active Abandoned
- 2000-11-16 EA EA200100782A patent/EA005169B1/ru not_active IP Right Cessation
- 2000-11-16 US US09/889,480 patent/US6891023B1/en not_active Expired - Fee Related
- 2000-11-16 MX MXPA01007261A patent/MXPA01007261A/es active IP Right Grant
- 2000-11-16 CN CNB008039542A patent/CN1230446C/zh not_active Expired - Fee Related
- 2000-11-16 AU AU15130/01A patent/AU783622B2/en not_active Ceased
- 2000-11-16 EP EP00977398A patent/EP1174441A2/en not_active Ceased
-
2001
- 2001-01-30 TW TW089126622A patent/TWI233440B/zh not_active IP Right Cessation
- 2001-07-13 ZA ZA200105803A patent/ZA200105803B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2359577A1 (en) | 2001-05-25 |
| AU783622B2 (en) | 2005-11-17 |
| ZA200105803B (en) | 2003-01-06 |
| JP2003514831A (ja) | 2003-04-22 |
| MXPA01007261A (es) | 2002-06-04 |
| TWI233440B (en) | 2005-06-01 |
| EA005169B1 (ru) | 2004-12-30 |
| AR026463A1 (es) | 2003-02-12 |
| EA200100782A1 (ru) | 2002-02-28 |
| KR20020008113A (ko) | 2002-01-29 |
| BR0007827A (pt) | 2001-10-30 |
| CN1344276A (zh) | 2002-04-10 |
| CN1230446C (zh) | 2005-12-07 |
| CO5280154A1 (es) | 2003-05-30 |
| AU1513001A (en) | 2001-05-30 |
| US6891023B1 (en) | 2005-05-10 |
| EP1174441A2 (en) | 2002-01-23 |
| KR100827627B1 (ko) | 2008-05-07 |
| WO2001036485A2 (es) | 2001-05-25 |
| WO2001036485A3 (es) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schultes et al. | Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43. 13 (Ab1) | |
| EA200301098A1 (ru) | Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей | |
| Jan Fagerberg et al. | Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A | |
| MX9504802A (es) | Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. | |
| PE20050422A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 | |
| NO933179L (no) | Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen | |
| MX9201016A (es) | Anticuerpos monoclonales humanizados y quimericos | |
| RU93055358A (ru) | V-области н-и l-цепей антител, химерные антитела, сдr-последовательности, l-и н-цепи антител, днк, вектор, клетка, способы получения антител | |
| DE60116753D1 (de) | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
| PT752876E (pt) | Anticorpos monoclonicos que se conectam com o percursor antigeneo de rejeicao de tumores mage-1, mage-1 recombinante, e peptidos imunogenicos derivados de mage-1 | |
| Abe et al. | Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies | |
| CU22921A1 (es) | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales | |
| US6794494B1 (en) | Cancerous disease modifying antibodies | |
| KR900701318A (ko) | 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체 | |
| US20050027106A1 (en) | Cancerous disease modifying antibodies | |
| WO2005019271A1 (en) | Anti-lewis y anti-idiotypic antibodies and uses thereof | |
| US20040141914A1 (en) | Cancerous disease modifying antibodies | |
| Saito et al. | Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer | |
| KR930019820A (ko) | 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도 | |
| DK0537168T3 (da) | Antigenet CTAA 28A32, som genkendes af MCA 28A32 | |
| ATE132906T1 (de) | Neuartige antiidiotypische monoklonale antikörper | |
| AU2007222843A1 (en) | Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and ovarian cancer | |
| CY1107163T1 (el) | Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων | |
| Xiang et al. | Production and characterization of a tumor-specific monoclonal antibody ACT19 recognizing an epitope distinctive from sialosyl-Tn on the TAG72 antigen | |
| REINSBERG et al. | Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43. 13? |